The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial
Table 2
Response regarding intensity of pain, allodynia, and hyperalgesia following lidocaine versus placebo intravenous infusion. The study included 20 patients who received twice the active (lidocaine) and twice the placebo drug.
Lidocaine
Placebo
Effect on intensity of pain
VAS score pretreatment (SD)
6.23 (1.56)
5.45 (2.04)
0.060
VAS score posttreatment (SD)
1.46 (1.37)
3.33 (2.02)
<0.001
VAS score at 16:00 (SD)
1.77 (1.61)
4.08 (2.33)
<0.001
VAS score at 20:00 (SD)
2.38 (1.73)
4.45 (2.36)
<0.001
VAS score at 24:00 (SD)
2.33 (1.84)
4.43 (2.15)
<0.001
VAS score at 08:00 next morning (SD)
2.95 (1.88)
5.20 (2.55)
<0.001
VAS reduction % pre-/posttreatment (SD)
76.4 (23.0)
40.1 (31.9)
<0.001
VAS reduction % pretreatment—16:00 (SD)
70.5 (27.7)
21.6 (45.5)
<0.001
VAS reduction % pretreatment—20:00 (SD)
59.5 (30.3)
20.2 (42.1)
<0.001
VAS reduction % pretreatment—24:00 (SD)
61.0 (32.1)
13.9 (39.1)
<0.001
VAS reduction % pretreatment—next day (SD)
52.0 (29.6)
−4.0 (56.3)
<0.001
Effect on allodynia
Reduced mechanical allodynia (%)
31 (77.5)
20 (50.0)
0.011
Reduced thermal allodynia (%)
18 (45.0)
7 (17.5)
0.008
Reduced cold allodynia (%)
15 (37.5)
5 (12.5)
0.010
Effect on hyperalgesia
Reduced pinprick hyperalgesia (%)
26 (65.0)
14 (35.0)
0.007
Reduced hot hyperalgesia (%)
22 (55.0)
7 (17.5)
<0.001
Reduced cold hyperalgesia (%)
20 (50.0)
11 (27.5)
0.039
VAS: visual analogue scale; SD: standard deviation.
